Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

Rhea-AI Summary

Sangamo Therapeutics to participate in Jefferies Cell & Genetic Medicine Summit

09/20/2023 - 04:15 PM

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City.

Sandy Macrae, Sangamo’s President and Chief Executive Officer is scheduled to present on Wednesday, September 27^th at 11:00AM ET. A live webcast of the presentation will be available here and on the Company’s Investor Events webpage. A replay of the presentation will be available on the Sangamo Therapeutics website for 90 days after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter.